r.rotation.to⌕ Search stocks, people, sectors
Request a free account

Follow the people · Insider

MW

Matthew T. Wiley

Insider · Chief Commercial Officer · DFTX

Matthew T. Wiley files insider transactions with the SEC as a chief commercial officer of Definium Therapeutics (DFTX). We hold 1 disclosed purchase or sale filed since 4 December 2018, 1 of them in the last 90 days.

  • Files forDFTX
  • Disclosed buys and sells1 in all, 1 in the last 90 days
  • Last disclosure12 August 2026

Positions held

6 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 3 February 2026 — 12 August 2026Chief Commercial Officer · Definium Therapeutics (DFTX)5 Form 4 lines · source: SEC Form 4
  • Filed 17 March 2025 — 17 March 2025Chief Commercial Officer · Mind Medicine (MindMed) (MNMD)1 Form 4 line · source: SEC Form 4
  • Filed 17 January 2022 — 3 October 2024Chief Commercial Officer · BioXcel Therapeutics (BTAI)16 Form 4 lines · source: SEC Form 4
  • Filed 30 September 2020 — 30 June 2021Chief Commercial Officer · VYNE Therapeutics (VYNE)7 Form 4 lines · source: SEC Form 4
  • Filed 9 March 2020 — 30 June 2020Chief Commercial Officer · Menlo Therapeutics (MNLO)11 Form 4 lines · source: SEC Form 4
  • Filed 3 December 2018 — 9 March 2020Chief Commercial Officer · Foamix Pharmaceuticals (FOMX)12 Form 4 lines · source: SEC Form 4

Everything they disclosed

52 entries, newest first — one per disclosure report, one per Form 4 line

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.